Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Company
Onxeo SA engages in the development of drugs for the treatment of cancer.The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP.It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad.The company was... 
Sector
Pharmaceuticals
Calendar
04/14Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Financials (€)
Sales 2014 28,1 M
EBIT 2014 4,24 M
Net income 2014 0,07 M
Finance 2014 37,0 M
Yield 2014 -
Sales 2015 5,45 M
EBIT 2015 -18,8 M
Net income 2015 -18,2 M
Finance 2015 19,4 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 6,40x
EV / Sales 2015 36,2x
Capitalization 217 M
More Financials
Latest news on BIOALLIANCE PHARMA SA
12/06 ONXEO : Reports on Positive DSMB Recommendation for Its Phase III Trial with Liv..
12/06 ONXEO : Reports on Positive DSMB Recommendation Phase III Trial
12/01 ONXEO : Updates on Positive DSMB Recommendation Phase III Trial
12/01 ONXEO : Updates on Positive DSMB Recommendation for Its Phase III Trial with Liv..
11/29 ONXEO : Gets Milestone Payment on Beleodaq
11/24 ONXEO : announces positive DSMB recommendation for its Phase III trial with Liva..
11/18 ONXEO : Secures Milestone Payment on Beleodaq
11/13 ONXEO : confirms receipt of the $25M milestone payment on Beleodaq® – Onxe..
More news
Sector news
1h ago ONO PHARMACEUTICAL : And gilead announce exclusive license agreement to develop ..
1h ago ROCHE BEARER SHARE : provides update on gantenerumab development programme
1h ago ROCHE BEARER SHARE : provides update on Phase III MARIANNE study in people with ..
More sector news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF